ABIVAX Société Anonyme (NASDAQ:ABVX) Given Consensus Recommendation of "Buy" by Analysts

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $38.67.

ABVX has been the topic of a number of analyst reports. JMP Securities started coverage on shares of ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $33.00 price target on the stock. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABVX. Point72 Asset Management L.P. grew its position in ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after purchasing an additional 119,300 shares during the period. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. Walleye Capital LLC grew its holdings in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after acquiring an additional 80,807 shares during the period. Finally, BNP Paribas Financial Markets increased its position in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after acquiring an additional 5,900 shares during the last quarter. Institutional investors own 47.91% of the company's stock.

ABIVAX Société Anonyme Trading Down 7.0 %

ABIVAX Société Anonyme stock traded down $0.54 during mid-day trading on Friday, hitting $7.12. The company had a trading volume of 338,692 shares, compared to its average volume of 98,969. ABIVAX Société Anonyme has a 12 month low of $6.65 and a 12 month high of $17.02. The stock's 50 day moving average price is $9.06 and its two-hundred day moving average price is $10.90.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.